Published:
Biomoda Awarded New Patent
ALBUQUERQUE, N.M. - (BUSINESS WIRE) - Biomoda, Inc. (OTCBB: BMOD), an Albuquerque-based cancer diagnostics
company, announces that it has received notice of allowance for a U.S.
Patent protecting the proprietary formula for the composition that binds
to cancer cells which is utilized in Biomoda's screening assay for the
early detection of cancer.
The U.S. Patent entitled "Method for Making 5, 10, 15, 20-Tetrakis
(Carboxyphenyl) Porphine (TCPP) Solution and Composition Comprising
TCPP," describes the new formulation of the Biomoda assay trademarked
under the name CyPath.
"This patent basically gives Biomoda a lock on the 'recipe' for the TCPP
Labeling Solution," said Biomoda President John Cousins. "Our
formulation moves beyond the original work done on TCPP at Los Alamos
National Laboratory and incorporates the cutting-edge science we are
doing in our own lab."
TCPP is the foundation for several Biomoda product lines and medical
diagnostics. The company's first product, an in-vitro test for the
detection of early-stage lung cancer, is currently in Phase II clinical
trials. Study volunteers provide deep-lung sputum samples to be screened
for cancer cells with the CyPath assay in the Biomoda lab. Results are
compared to CT scans and Pap stains read by independent radiologists and
cytopathologists, respectively, to confirm accuracy.
Biomoda is seeking Food and Drug Administration (FDA) approval of its
cytology-based screening technology as a Class III medical device.
Multi-site Phase III trials, the final step before FDA approval, are
scheduled to begin in early 2010.
In addition to U.S. patents (6,838,248 and 7,384,764), Biomoda also
holds patents for its proprietary technology in several foreign
countries.
Biomoda (www.biomoda.com)
is a cancer diagnostics company focused on the development of accurate,
inexpensive and noninvasive tests for the early detection of cancer in
large populations. In addition to its first product for lung cancer,
diagnostic assays for cervical, breast, colorectal, bladder, and oral
cancers are targeted for development.
Biomoda, Inc.
John Cousins, 505-821-0875
Copyright © 2009, Business Wire, Inc., All rights reserved.
Copyright © 2009, NewsBlaze,
Daily NewsTags: Business wire, Healthcare, new mexico, new york, Women in the News, Health, Biotechnology, Medical, Consulting, Accounting and other Professional Services, Insurance
Search News
Daily News
